Form 4: Opus Genetics Executive Granted 86,500 Restricted Stock Units

Opus Genetics' Head of Financial Quality Assurance, Amy Zaremba, was granted 86,500 restricted stock units.

Summary

• Amy Zaremba, Head of Financial Quality Assurance at Opus Genetics, Inc., acquired 86,500 shares of common stock.
• The transaction occurred on January 22, 2026.
• The acquisition was a grant of restricted stock units (RSUs) with a price of $0 per share.
• Following this transaction, Amy Zaremba beneficially owns 193,128 shares of common stock.
• The RSUs will vest in substantially equal quarterly installments over the next sixteen quarters, contingent on continued service.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a key executive is a positive signal for long-term alignment of management and shareholder interests, reflecting standard compensation practices.

Positives

• Increased alignment of management interests with shareholders through equity ownership.
• The grant of restricted stock units serves as a long-term incentive for the Head of Financial Quality Assurance.
• The reporting person's beneficial ownership increased to 193,128 shares, demonstrating a significant stake in the company.

Negatives

• The grant of 86,500 restricted stock units could lead to minor dilution for existing shareholders upon vesting, though this is a standard compensation practice.

Future Outlook

The restricted stock units will vest in substantially equal quarterly installments over the next sixteen quarters, subject to the reporting person's continuing service, indicating a long-term commitment and incentive structure.

Industry Context

The grant of restricted stock units is a common form of equity compensation used across various industries to attract, retain, and incentivize key executives and employees, aligning their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• This RSU grant is consistent with typical executive compensation practices in the biotechnology and pharmaceutical sectors, where equity-based incentives are frequently used to reward performance and ensure long-term commitment. Specific comparable companies or projects are not detailed in this filing, but such grants are standard for executives at similar-stage companies.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting, but also increased alignment of executive interests with long-term shareholder value.
• Employees: Reflects standard executive compensation practices, potentially signaling stability in leadership.
• Management: Provides a significant long-term incentive and equity stake in the company.

Next Steps

• The restricted stock units will vest in substantially equal quarterly installments over the next sixteen quarters, contingent on the reporting person's continued service.

Key Dates

Recommendation

This Form 4 filing reports a standard equity compensation grant to an executive, which is a routine event and typically does not significantly alter the investment thesis for a company. While it signals management alignment, it's not a catalyst for a strong buy or sell recommendation on its own. Investors should consider this in the broader context of the company's financial performance and strategic outlook.

Keywords

Opus Genetics, IRD, SEC Form 4, insider transaction, restricted stock units, RSU grant, executive compensation, beneficial ownership, equity compensation